



ASX / Media Release
26 November 2015

Media interview on CE Mark and Growth Plans

SYDNEY, 26th November, 2015: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to provide details of an interview with Chief Executive Officer and Managing Director Daniel Kenny and Finance News Network to discuss the Company's CE Mark progress and growth plans.

The interview can be viewed via the OncoSil Medical company website; via this link: [Media interview on CE Mark and Growth Plans](#)

OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSil™ localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSil™ for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.

The Company was granted a Fast Track review for its CE Mark with the European regulator in October this year and expects to receive the outcome of its CE Mark application in the near future.

ENDS

Contact:

Mr Daniel Kenny
Chief Executive Officer and Managing Director
E: daniel.kenny@oncosil.com.au
T: +61 2 9223 3344

James Moses
Mandate Corporate
E: james@mandatecorporate.com.au
M: +61 420 991 574
T: +61 2 8211 0612

About OncoSil Medical Ltd

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma liver cancer

Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. It's very poor prognosis makes HCC the third leading cause of cancer related mortality responsible for approximately 600,000 deaths annually. Hepatocellular carcinoma can be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years depending on the liver function at diagnosis and the extent of tumour invasion. The value of the hepatocellular cancer (HCC) market is expected to triple in size to \$1.4b by 2019.

References

- Global Industry Analysts 2010
- BIOSDP-201. A single dose, single centre open label Phase I/II Safety Study in Hepatocarcinoma
- Venook et al. The incidence of Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist; 15 Supplement 5-13
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics>
- <http://www.datamonitorhealthcare.com/hepatocellular-cancer-market-to-treble-in-size-by-2019>
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics>